Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma

Clinical Epigenetics

Giancarlo Latte¹  Attilio Gabbas¹  Laura Pilo¹  Francesco Vacca¹  Rosanna Asproni¹  Anna Calvisi¹  Angelo D Palmas¹  Maria Monne¹  Giovanna Piras¹ 

[1] UOC Ematologia, Ospedale “San Francesco”, ASL Nuoro. Via Mannironi 1, Nuoro, 08100, Italy

关键词: PTEN;    Akt pathway;    multiple myeloma;    Promoter hypermethylation;   

Others  :  1092830
DOI  :  10.1186/1868-7083-6-16

 received in 2014-04-24, accepted in 2014-08-12,  发布年份 2014

【 摘 要 】

Background

Aberrant DNA methylation of promoter region CpG islands is an alternative mechanism that leads to genetic defects in the inactivation of tumor suppressor genes during myelomagenesis. The aim of this study was to examine the promoter methylation status of the phosphates and tensin homologue on chromosome 10 (PTEN) gene in a cohort of multiple myeloma patients.

Findings

The PTEN gene was hypermethylated in 7 out of 58 (12%) primary myeloma samples. The correlation between functional inactivation and PTEN mRNA levels was not statistically significant. The multiple myeloma subgroup with an aberrant PTEN status had a prevalence of the component IgG, Salmon Durie stage I, lower lactate dehydrogenase levels, intermediate-standard cytogenetic risk and longer overall survival with the respect to the unmethylated subgroup.

Conclusions

This is the first report demonstrating the presence of PTEN promoter hypermethylation in multiple myeloma.

【 授权许可】

   
2014 Piras et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ: Aberrant global methylation patterns affect the molecular pathogenesis and prognosisof multiple myeloma. Blood 2011, 117:553-562.
• [2]Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB: Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. Journal of Immunology 2013, 190:2966-2975.
• [3]Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE, Morgan GJ: Global methylation analysis identifies prognosticallyimportantepigeneticallyinactivatedtumoursuppressorgenesin multiple myeloma. Blood 2013, 122:219-226.
• [4]Chim CS, Pang R, Fung TK, Choi CL, Liang R: Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007, 21:2527-2536.
• [5]Chim CS, Kwong YL, Liang R: Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin Lymphoma Myeloma 2008, 8:331-339.
• [6]Gonzalez-Paz N, Cheng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R: Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109:1228-1232.
• [7]Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
• [8]Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362.
• [9]Song MS, Salmena L, Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13:283-296.
• [10]Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK: Analysis of PTEN deletion and mutation in multiple myeloma. Leuk Re 2006, 30:262-265.
• [11]Ge NL, Rudikoff S: Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene 2000, 19:4091-4095.
• [12]Wang SY, Hao HL, Deng K, Li Y, Cheng ZY, Lv C, Liu ZM, Yang J, Pan L: Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration. Leuk Lymphoma 2012, 53:1162-1168.
• [13]Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ: Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification ofMyeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013, 88:360-376.
• [14]Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
• [15]Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D: Methylation of the PTEN promoter define slow-grade gliomas and secondary glioblastoma. Neuro Oncol 2007, 92:71-79.
• [16]Liu AJ, Furusato B, Ravindranath L, Chen YM, Srikantan V, McLeod DG, Petrovics G, Srivastava S: Quantitative analysis of a panel of gene expression in prostate cancer-with emphasis on NPY expression analysis. J Zhejiang Univ Sci B 2007, 8:853-859.
• [17]Montiel-Duarte C, Cordeu L, Agirre X, Román-Gómez J, Jiménez-Velasco A, José-Eneriz ES, Gárate L, Andreu EJ, Calasanz MJ, Heiniger A, Torres A, Prósper F: Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Re 2008, 32:709-716.
• [18]Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P: Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013, 19:2096-2106.
• [19]Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E: Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers 2013, 5:430-461.
• [20]Hu J, Huang X, Hong X, Lu Q, Zhu X: Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway. Cancer Cell Int 2013, 13:25-37.